Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Net Income towards Common Stockholders (2016 - 2017)

Historic Net Income towards Common Stockholders for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$544000.0.

  • Soleno Therapeutics' Net Income towards Common Stockholders rose 7918.41% to -$544000.0 in Q4 2017 from the same period last year, while for Sep 2018 it was -$544000.0, marking a year-over-year increase of 9039.27%. This contributed to the annual value of -$175.8 million for FY2024, which is 35315.16% down from last year.
  • As of Q4 2017, Soleno Therapeutics' Net Income towards Common Stockholders stood at -$544000.0, which was up 7918.41% from -$1.3 million recorded in Q3 2017.
  • Soleno Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$544000.0 during Q4 2017, with a 5-year trough of -$6.4 million in Q3 2016.
  • For the 5-year period, Soleno Therapeutics' Net Income towards Common Stockholders averaged around -$2.3 million, with its median value being -$2.0 million (2014).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 37925.27% in 2014, then surged by 8024.87% in 2017.
  • Over the past 5 years, Soleno Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$869278.0 in 2013, then plummeted by 379.25% to -$4.2 million in 2014, then soared by 31.72% to -$2.8 million in 2015, then increased by 8.13% to -$2.6 million in 2016, then skyrocketed by 79.18% to -$544000.0 in 2017.
  • Its Net Income towards Common Stockholders was -$544000.0 in Q4 2017, compared to -$1.3 million in Q3 2017 and -$913000.0 in Q2 2017.